Related Experiment Video

Updated: Oct 2, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

[The inhibitory effect of bcl-2 antisense oligodeoxynucleotide/RNA on the growth of cervical carcinoma in vitro]

R Mi1, H Wang, Q Qu

  • 1Department of Obstetrics and Gynecology, General Hospital, Tianjin Medical University, Tianjin 300052, China.

Zhonghua Fu Chan Ke Za Zhi
|January 26, 2002
PubMed
Abstract

Insights

Bcl-2 antisense oligodeoxynucleotide (ODN) effectively inhibits human cervical carcinoma cell growth and induces apoptosis in vitro. This study supports bcl-2 gene therapy for cervical cancer.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Gene Therapy

Context:

  • Human cervical carcinoma exhibits elevated bcl-2 protein and mRNA expression.
  • Antisense technology offers a potential therapeutic strategy for targeting specific gene expression.

Purpose:

  • To investigate the therapeutic efficacy of bcl-2 antisense oligodeoxynucleotide (ODN)/RNA in human cervical carcinoma cells in vitro.
  • To evaluate the impact of bcl-2 antisense ODN/RNA on Hela cell growth and apoptosis.

Summary:

  • Transfection of Hela cells with bcl-2 antisense ODN/RNA significantly reduced bcl-2 protein and mRNA levels.
  • Antisense ODN demonstrated a dose-dependent inhibition of Hela cell growth and survival, with optimal effects observed at 10 micromol/L after 24 hours.
  • Recombinant retroviral vector pDOR-AB successfully integrated the antisense bcl-2 gene into Hela cells, leading to decreased bcl-2 expression and induced apoptosis.

Impact:

  • The findings establish the feasibility of targeting the bcl-2 gene for antisense gene therapy in human cervical carcinoma.
  • Provides a theoretical basis and experimental evidence for future in vivo studies and development of novel cancer treatments.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...